ArticleMolecular pain
Resveratrol alleviates neuropathic pain after spinal cord injury by suppressing δ-catenin palmitoylation-mediated membrane accumulation of Nav1.6 in the spinal dorsal horn.
Article in Molecular pain. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic pain is a severe adverse complication of spinal cord injury (SCI) for which effective therapies are currently lacking. Resveratrol, a natural phytoalexin found in many plants and fruits, has been shown to relieve chemotherapy- and nerve injury-induced neuropathic pain and to promote functional recovery after SCI. In this study, we found that intraperitoneal administration of resveratrol increased the expression and activity of silent information regulator 1 (SIRT1) in the rat spinal dorsal horn and markedly attenuated neuropathic pain after SCI while improving motor recovery. Building on our previous finding that palmitoylation of δ-catenin promotes the membrane trafficking of the voltage-gated sodium channel Nav1.6 in dorsal root ganglion neurons and contributes to oxaliplatin- and nerve injury-induced neuropathic pain, we further examined whether resveratrol produces analgesia by inhibiting δ-catenin palmitoylation-mediated membrane accumulation of Nav1.6 in the spinal dorsal horn after SCI. Our results showed that SCI markedly increased both Nav1.6 membrane localization and δ-catenin palmitoylation in the dorsal horn and intrathecal delivery of Nav1.6 shRNA or pharmacological inhibition of palmitoylation with 2-bromopalmitate significantly attenuated mechanical allodynia after SCI. Resveratrol suppressed SCI-induced δ-catenin palmitoylation and reduced the pathological membrane accumulation of Nav1.6, an effect accompanied by downregulation of the palmitoyl acyltransferase ZDHHC3 (DHHC3). Together, these findings indicate that resveratrol alleviates neuropathic pain after SCI by inhibiting DHHC3-mediated δ-catenin palmitoylation and thereby suppressing the membrane trafficking of Nav1.6 in the spinal dorsal horn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.